Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized trial of biologics for treatment-refractory ulcerative colitis
jRCT1031200329Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial in autoimmune colitis comparing Infliximab arm, Vedolizumab arm and Ustekinumab arm (3 arms). Primary endpoint: Clinical remission rate at Week 12. Started May 2021; status: completed.
02
Drugs
infliximabvedolizumabustekinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT1031200329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031200329.